ArticleDrug design, development and therapy2026
Structural Prerequisites for Pim-1 Kinase Inhibition and the Identification of a Pyrazolyl-Methylene-Indolinone Hit.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pim-1 is a serine/threonine kinase of the pan-Pim family (Pim-1, -2, and -3), whose overexpression is associated with various cancers. Its distinctive hinge-region architecture provides opportunities for selective inhibitor development, with several inhibitors reported as clinical candidates. Understanding structure-activity relationships is essential for distinguishing biologically active compounds from high-scoring docking hits, a major challenge in structure-based drug discovery. Methods: A virtual screening workflow comprising Glide docking and Induced Fit Docking (IFD) was applied to approximately 900,000 commercially available compounds. Six structurally diverse compounds were selected for in vitro Pim-1 inhibitory activity evaluation. Molecular dynamics (MD) simulations and quantum mechanical (QM) calculations were subsequently performed to investigate the structural determinants of inhibitory activity. Results: Among the tested compounds, compound Discussion: These findings provide insight into the structural and conformational requirements for productive Pim-1 inhibition and highlight the value of integrating docking, MD simulations, and QM calculations during the search for novel inhibitors. The identified hit represents a previously unreported scaffold for Pim-1 inhibition that may provide a starting point for future optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.